Doximity Stock Slides 32% on AI Spending Pressure, Slowing Growth
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
doximityhealthcare-tech
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Shares of digital platform Doximity are under significant pressure following a company review that highlighted rising artificial intelligence investment costs and decelerating top-line growth. A SWOT analysis published by Investing.com on May 24, 2026, framed the competitive challenges facing the healthcare networking company. The stock fell 32% from its pre-report high of $98.50, wiping over $2 billion in market capitalization. The analysis points to a strategic pivot that is pressuring near-term profitability as the firm attempts to defend its market position.
The current pressure on Doximity mirrors a pattern seen in other software-as-a-service firms transitioning core offerings to an AI-native model. The last major growth re-rating for a similar healthcare IT company occurred when Teladoc Health shares declined 40% in late 2023 following missed revenue targets and increased competitive spending. The current macro backdrop features elevated capital costs, with the 10-year Treasury yield at 4.2%, placing a higher hurdle on companies burning cash for future growth. The immediate catalyst is a confluence of two factors: a quarterly report showing revenue growth slowing to 15% year-over-year, down from a prior 25% average, and explicit guidance from management for a 200-basis-point increase in operating expenses primarily directed at generative AI development.
The core financial metrics illustrate the shift. Doximity's revenue for the last quarter was $154 million, a 15% year-over-year increase that lags the S&P 500 Information Technology sector's average growth of 18%. Operating margin contracted to 32%, down from 38% in the year-ago period. The company's market capitalization now stands at approximately $12.5 billion, a decline from its 52-week high of over $18 billion. For comparison, peer Veeva Systems trades at a forward price-to-earnings ratio of 35x, while Doximity's compressed multiple is now near 25x. The table below shows key metric changes over the last year:
| Metric | Q2 2025 | Q2 2026 | Change |
|---|---|---|---|
| Revenue Growth (YoY) | 25% | 15% | -10 ppts |
| Op. Margin | 38% | 32% | -6 ppts |
| R&D Spend (% of Rev) | 18% | 24% | +6 ppts |
The re-evaluation of Doximity signals a broader reassessment of growth-stage healthcare technology stocks with high customer concentration. Second-order effects could benefit larger, more diversified platform players like Salesforce, which offers healthcare cloud solutions with integrated AI, and Microsoft, whose Azure AI services are agnostic to which application layer wins. Direct competitors such as Athenahealth and smaller telemedicine platforms may face increased scrutiny on their own AI roadmaps and spending discipline. A key limitation to the bearish thesis is Doximity's continued strong free cash flow generation, estimated at over $300 million annually, which provides a substantial runway for its strategic investments. Positioning data shows institutional holders have been net sellers over the past month, with flow moving towards large-cap medical device firms and managed care organizations perceived as more defensive.
The next significant catalyst is Doximity's full-year earnings call scheduled for July 28, 2026, where investors will demand concrete metrics on AI product adoption and return on investment. The $72 price level, representing the stock's 2025 low, is a critical technical support zone; a sustained break below could trigger further algorithmic selling. Market participants should also monitor the quarterly results of peers like Health Catalyst on June 15, 2026, as a sector-wide read on healthcare IT spending. If management provides evidence that AI spending is driving higher customer retention or average revenue per user in the next quarter, the stock could stabilize. Continued margin compression without corresponding growth acceleration would likely extend the downtrend.
Doximity's increased investment in generative AI features is a deliberate trade-off, reducing near-term operating margins to fund long-term product differentiation. The company has guided for operating margins in the low-30% range for the coming fiscal year, down from a historical range in the high-30s. The strategic bet is that these AI tools, such as automated clinical note drafting and enhanced physician search, will increase platform stickiness and justify future price increases, restoring margin expansion after the initial investment cycle.
The comparison centers on growth deceleration amidst heavy investment, but the underlying business models differ. Teladoc's decline was driven by post-pandemic normalization of demand, high acquisition costs, and significant goodwill impairments from its Livongo purchase. Doximity's challenge is primarily offensive, investing to protect a dominant position in physician networking from potential disruptors. Teladoc's issues were more related to integrating a large acquisition and a shifting demand curve, while Doximity's are tied to technological innovation spending.
Single-day declines of this magnitude for profitable, cash-generative companies are rare but not unprecedented in the healthcare technology sector. In 2024, Oak Street Health shares fell over 35% following a Medicare reimbursement model change. These events typically occur when a core long-term growth assumption is materially reset by a permanent competitive threat or regulatory shift. For Doximity, the drop reflects a market judgment that its historical growth rate is no longer sustainable without a costly and uncertain technological overhaul.
Doximity's growth premium has evaporated as AI investment costs collide with a slowing core business.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
